Phase II study of combination of the HyperCVAD regimen with dasatinib in patients with Philadelphia chromosome (Ph) or BCR-ABL positive acute lymphoblastic leukemia (ALL) and lymphoid blast phase chronic myeloid leukemia (CML-LB)

被引：6

作者：

Ravandi, Farhad ^{[1
]}

Thomas, Deborah ^{[1
]}

Kantarjian, Hagop ^{[1
]}

Faderl, Stefan ^{[1
]}

Koller, Charles ^{[1
]}

Brown, Devri ^{[1
]}

Garris, Rebecca ^{[1
]}

Borthakur, Gautam ^{[1
]}

Burger, Jan ^{[1
]}

Kebriaei, Partow ^{[1
]}

Jorgensen, Jeffrey ^{[1
]}

Jones, Dan ^{[1
]}

Cortes, Jorge ^{[1
]}

O'Brien, Susan ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

10.1182/blood.V110.11.2814.2814

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2814

引用

页码：828A / 828A

页数：1

共 50 条

[21] Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study
Macaron, Walid
Kantarjian, Hagop
Short, Nicholas
Jain, Nitin
Huang, Xuelin
Montalban-Bravo, Guillermo
Kadia, Tapan M.
Daver, Naval
Chien, Kelly S.
Alvarado, Yesid
Garcia-Manero, Guillermo
Issa, Ghayas C.
Haddad, Fadi
Kwari, Monica
Delumpa, Ricardo
Mayor, Ejiroghene
Deen, Wuliamatu
Thankachan, Jennifer
Loiselle, Christopher
Rivera, Juan
Milton, Anna
Waller, Lourdes
Banks, Glenda
Garris, Rebecca
Konopleva, Marina
Ravandi, Farhad
Jabbour, Elias
BLOOD, 2022, 140 : 8973 - 8975
[22] Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia
Hisashi Sakamaki
Ken-ichi Ishizawa
Masafumi Taniwaki
Shin Fujisawa
Yasuo Morishima
Kensei Tobinai
Masaya Okada
Kiyoshi Ando
Noriko Usui
Shuichi Miyawaki
Atae Utsunomiya
Nobuhiko Uoshima
Tadashi Nagai
Tomoki Naoe
Toshiko Motoji
Itsuro Jinnai
Mitsune Tanimoto
Yasushi Miyazaki
Kazunori Ohnishi
Shinsuke Iida
Shinichiro Okamoto
Taku Seriu
Ryuzo Ohno
International Journal of Hematology, 2009, 89 : 332 - 341
[23] Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia
Sakamaki, Hisashi
Ishizawa, Ken-ichi
Taniwaki, Masafumi
Fujisawa, Shin
Morishima, Yasuo
Tobinai, Kensei
Okada, Masaya
Ando, Kiyoshi
Usui, Noriko
Miyawaki, Shuichi
Utsunomiya, Atae
Uoshima, Nobuhiko
Nagai, Tadashi
Naoe, Tomoki
Motoji, Toshiko
Jinnai, Itsuro
Tanimoto, Mitsune
Miyazaki, Yasushi
Ohnishi, Kazunori
Iida, Shinsuke
Okamoto, Shinichiro
Seriu, Taku
Ohno, Ryuzo
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 89 (03) : 332 - 341
[24] Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
Druker, BJ
Sawyers, CL
Kantarjian, H
Resta, DJ
Reese, SF
Ford, JM
Capdeville, R
Talpaz, M
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14): : 1038 - 1042
[25] Dasatinib (Sprycel®) in patients with philadelphia chromosome-positive acute lymphoblastic leukemia or lymphoid blast phase chronic myeloid leukemia after imatinib failure:: A single-center experience
Piccaluga, P. P.
Rosti, G.
Rondoni, M.
Amabile, M.
Bosi, C.
Castagnetti, F.
Iacobucci, L.
Laterza, C.
Palandri, F.
Paolini, S.
Soverini, S.
Verlicchi, L.
Visani, G.
Baccarani, M.
Martinelli, G.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 181 - 182
[26] Outcome of Patients With Chronic Myeloid Leukemia in Lymphoid Blastic Phase and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated With Hyper-CVAD and Dasatinib
Morita, Kiyomi
Kantarjian, Hagop M.
Sasaki, Koji
Issa, Ghayas C.
Jain, Nitin
Konopleva, Marina
Short, Nicholas J.
Takahashi, Koichi
DiNardo, Courtney D.
Kadia, Tapan M.
Garcia-Manero, Guillermo
Daver, Naval
Montalban Bravo, Guillermo
Cortes, Jorge E.
Ravandi, Farhad
Jabbour, Elias
CANCER, 2021, 127 (15) : 2641 - 2647
[27] SAFETY AND TOLERABILITY OF DASATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) AND PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH plus ALL): POOLED ANALYSIS OF OVER 2400 PATIENTS
Saglio, G.
le Coutre, P.
Cortes, J.
Mayer, J.
Rowlings, P.
Subar, M.
Preston, J.
Shah, N.
HAEMATOLOGICA, 2014, 99 : 329 - 329
[28] Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive (PH plus ) Chronic Myeloid Leukemia (CML) or PH plus Acute Lymphoblastic Leukemia (ALL): a Pharmacokinetic Study
Hijiya, Nobuko
Zwaan, C. Michel
Rizzari, Carmelo
Foa, Roberto
Abbink, Floor
Lancaster, Donna
Landman-Parker, Judith
Millot, Frederic
Moppett, John
Nelken, Brigitte
Ducassou, Stephane
Putti, Maria Caterina
Tian, Xianbin
Sinclair, Karen
Santanastasio, Helene
Buchbinder, Aby
Kearns, Pamela
PEDIATRIC BLOOD & CANCER, 2017, 64 : S34 - S34
[29] Results of a phase II study of STI in adults patients with Philadelphia chromosome positive Chronic Myeloid Leukemia in Chronic Phase (CML).
Guilhot, F
Kantarjian, H
Sawyers, C
Hochhaus, A
Schiffer, C
Resta, D
Capdeville, R
Druker, B
LEUKEMIA, 2001, 15 (03) : 488 - 488
[30] Dasatinib (BMS-354825) in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph plus ALL) who are resistant or intolerant to imatinib: Update of a phase I study.
Sawyers, CL
Kantarjian, H
Shah, N
Cortes, J
Paquette, R
Donato, N
Nicoll, J
Bleickardt, E
Chen, TT
Talpaz, M
BLOOD, 2005, 106 (11) : 16A - 16A

← 1 2 3 4 5 →